Oric Pharmaceuticals, Inc. ORIC
Oric Pharmaceuticals, Inc. (Nasdaq: ORIC) is an oncology drug developer. Its lead program, rinzimetostat (ORIC-944), is in Phase 3 for metastatic castration-resistant prostate cancer (post-abiraterone), in combination with darolutamide. Its next catalyst on record is enozertinib (ORIC-114): The Company plans to initiate Redwood-1, a global Phase 3 registrational trial in EGFR atypical NSCLC in 1H 2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: enozertinib (ORIC-114) — The Company plans to initiate Redwood-1, a global Phase 3 registrational trial in EGFR atypical NSCLC in 1H 2027. (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rinzimetostat + darolutamide (Himalayas-1, Phase 3) | post-abiraterone mCRPC | small molecule | Phase 3 |
| rinzimetostat + apalutamide / darolutamide (Phase 1b dose optimization) | mCRPC | small molecule | Phase 1 |
| enozertinib (ORIC-114; Phase 1b) | NSCLC with EGFR exon 20 insertion and atypical (PACC) mutations | small molecule | Phase 1 |
Recent results and decisions
- Oct 23, 2026positive Enozertinib Phase 1b trial in 1L EGFR atypical NSCLC achieved 84% confirmed systemic ORR, 70% confirmed CNS ORR, and 88% 6-month landmark PFS.
Enozertinib demonstrated meaningful systemic activity, including: 84% (21 of 25) confirmed systemic ORR by investigator.
Filing - Oct 23, 2026met Enozertinib Phase 1b trial achieved 84% confirmed systemic ORR and 70% confirmed CNS ORR in first-line EGFR atypical NSCLC with no treatment-related discontinuations.
Enozertinib demonstrated meaningful systemic activity, including 84% (21 of 25) confirmed systemic ORR by investigator and 80% (20 of 25) confirmed systemic ORR by BICR.
Filing - Sep 4, 2026positive Enozertinib Phase 1b trial achieved 84% confirmed systemic ORR and 70% confirmed CNS ORR in 1L EGFR atypical NSCLC with 88% 6-month landmark PFS.
Enozertinib demonstrated meaningful systemic activity, including: 84% (21 of 25) confirmed systemic ORR by investigator. 80% (20 of 25) confirmed systemic ORR by BICR.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.